modelLacosamide
Extends from Pharmacolibrary.Drugs.ATC.N.N03AX18.
Information
| name: | Lacosamide | |
| ATC code: | N03AX18 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 0.6 | L |
| clearance: | 0.96 | L/h/kg |
| other parameters in model implementation | ||
Lacosamide is an antiepileptic drug (AED) approved for the treatment of partial-onset seizures in patients with epilepsy. It acts by enhancing the slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes. Lacosamide is used as adjunctive therapy or monotherapy in adults and children, and is generally well-tolerated.
Pharmacokinetics
Pharmacokinetics in healthy adult volunteers after oral administration at steady state.
References
Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590
Hoy, SM (2018). Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy. CNS drugs 32(5) 473–484. DOI:10.1007/s40263-018-0523-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29785508
Verrotti, A, et al., & Zaccara, G (2012). Lacosamide in patients with pharmacoresistant epilepsy. Expert opinion on pharmacotherapy 13(14) 2065–2072. DOI:10.1517/14656566.2012.713347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22873760
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)